×
  • Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Mastitis Market Share

    ID: MRFR/Pharma/3936-CR
    142 Pages
    Rahul Gotadki
    July 2019

    Mastitis Market Research Report Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), End User (Veterinary Centers and Hospital & Clinics) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Mastitis Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Share

    Mastitis Market Share and Foresight

    Mastitis is when a woman's breast tissue becomes swollen or inflamed, usually due to an infection in the breast ducts. This often happens to women who are breastfeeding. As more women become pregnant and choose to breastfeed, the mastitis market is growing. For example, in the European Union, around 5.1 million babies were born in 2016, according to Eurostat. In the United States, there were over 3,853,472 reported births in 2017, as stated by the Centers for Disease Control and Prevention. New Zealand also saw a significant number of births, with over 59,193 women giving birth and 59,494 babies born in 2015, according to the Ministry of Health. Since mastitis is more common in breastfeeding women, the increasing number of births contributes to the growth of the mastitis market. Bovine mastitis is a similar condition but occurs in cows. It happens when infectious microbes invade the udder tissue, usually due to contagious or environmental pathogens. Factors like contaminated milking instruments, improperly cleaned milking units, dirty water used for udder cleaning, and unclean bedding contribute to bovine mastitis. The National Center for Biotechnology Information reported a high prevalence of mastitis in cows, with a herd-level prevalence of 74.7% and a cow-level prevalence of 62.6% in 2015. This widespread occurrence causes significant losses to the dairy industry, with the United States alone losing over USD 2 billion annually. The lack of routine mastitis prevention and control practices by herd owners contributes to these losses. To address this, there's a need for increased awareness among dairy farmers about hygienic milking practices, regular screening for sub-clinical mastitis, implementing dry cow therapy, and culling chronically infected cows. Understanding the factors leading to mastitis in both women and cows is crucial for developing effective solutions. As more women choose breastfeeding and the dairy industry continues to thrive, the mastitis market is expected to grow. This growth emphasizes the importance of implementing preventive measures and maintaining proper hygiene in both healthcare and farming practices to address the challenges associated with mastitis.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch

    Leave a Comment

    FAQs

    At what CAGR is the mastitis market projected to grow in the forecast period (2024-2032)?

    Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).

    How much is the mastitis market worth in the future?

    The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.

    What are the major tailwinds pushing the growth of the global mastitis market?

    Increasing need for better treatments and government funding support for R&D are major tailwinds pushing the growth of the global mastitis market.

    Which region holds the largest share in the global mastitis market?

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global mastitis market?

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    Market Summary

    As per MRFR analysis, the Mastitis Market Size was estimated at 27.58 USD Billion in 2024. The Mastitis industry is projected to grow from 32.2 in 2025 to 151.24 by 2035, exhibiting a compound annual growth rate (CAGR) of 16.73 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Mastitis Market is experiencing a dynamic shift driven by technological advancements and changing consumer demands.

    • Technological advancements in diagnostics are enhancing the detection and management of mastitis in both bovine and human populations.
    • North America remains the largest market for mastitis treatments, while the Asia-Pacific region is emerging as the fastest-growing market.
    • Bovine mastitis treatment, particularly through antibiotics, continues to dominate the market, whereas human mastitis solutions are witnessing rapid growth.
    • The rising incidence of mastitis in dairy cattle and growing awareness of animal health are key drivers propelling market expansion.

    Market Size & Forecast

    2024 Market Size 27.58 (USD Billion)
    2035 Market Size 151.24 (USD Billion)
    CAGR (2025 - 2035) 16.73%
    Largest Regional Market Share in 2024 Europe

    Major Players

    <p>Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Cegelec (FR), Vetoquinol (FR), Huvepharma (BG), Phibro Animal Health (US), Dechra Pharmaceuticals (GB)</p>

    Market Trends

    The Mastitis Market is currently experiencing notable transformations driven by various factors. The increasing awareness regarding animal health and welfare is prompting dairy farmers to adopt better management practices. This shift is likely to enhance the overall quality of milk production, thereby influencing the demand for effective mastitis treatment solutions. Furthermore, advancements in veterinary medicine and technology are facilitating the development of innovative therapies and diagnostic tools, which may improve the detection and management of mastitis in livestock. As a result, stakeholders in the Mastitis Market are focusing on research and development to create more efficient products that cater to the evolving needs of the industry. In addition, the rising prevalence of mastitis in dairy herds is compelling producers to seek preventive measures and treatments. This trend suggests a growing market for both pharmaceuticals and alternative therapies aimed at reducing the incidence of this condition. Moreover, regulatory changes and increased scrutiny on antibiotic use in livestock are likely to drive the demand for non-antibiotic treatment options. Overall, the Mastitis Market appears poised for growth as it adapts to these emerging challenges and opportunities, fostering a more sustainable approach to dairy farming.

    Technological Advancements in Diagnostics

    The Mastitis Market is witnessing a surge in the adoption of advanced diagnostic tools. Innovations such as rapid testing kits and digital monitoring systems are enhancing the ability to detect mastitis early. This trend is likely to lead to timely interventions, reducing the overall impact of the disease on dairy production.

    Shift Towards Preventive Care

    There is a noticeable shift in focus towards preventive care within the Mastitis Market. Dairy producers are increasingly investing in management practices that aim to prevent mastitis outbreaks. This proactive approach may result in a decline in treatment costs and improved herd health.

    Regulatory Changes Impacting Treatment Options

    Regulatory frameworks surrounding antibiotic use in livestock are evolving, influencing the Mastitis Market. Stricter guidelines are prompting the development of alternative treatment options. This trend indicates a potential shift towards more sustainable practices in managing mastitis.

    Mastitis Market Market Drivers

    Growing Awareness of Animal Health

    There is a notable increase in awareness regarding animal health, particularly among dairy farmers and consumers. This heightened awareness is driving the Mastitis Market as stakeholders recognize the importance of maintaining herd health for sustainable production. Educational initiatives and outreach programs have been implemented to inform farmers about the implications of mastitis on animal welfare and economic viability. Consequently, this awareness is fostering a demand for advanced diagnostic tools and treatment options, thereby stimulating growth within the Mastitis Market. The emphasis on animal welfare is expected to continue influencing purchasing decisions in the coming years.

    Increasing Demand for Dairy Products

    The rising demand for dairy products is a crucial factor propelling the Mastitis Market. As consumer preferences shift towards dairy consumption, the pressure on dairy producers to maintain high-quality milk production intensifies. This demand compels farmers to adopt effective mastitis management strategies to ensure optimal milk yield and quality. Reports suggest that the dairy market is projected to grow at a compound annual growth rate of 3.5 percent over the next five years. Consequently, the Mastitis Market is poised to benefit from this trend, as producers seek solutions to combat mastitis and enhance overall herd productivity.

    Advancements in Treatment Technologies

    Technological advancements in treatment options are significantly influencing the Mastitis Market. Innovations such as targeted therapies and improved antibiotic formulations are emerging, providing more effective solutions for managing mastitis. The introduction of non-antibiotic alternatives, including immunomodulators and herbal treatments, is also gaining traction. These advancements not only enhance treatment efficacy but also align with the growing demand for sustainable practices in livestock management. As a result, the Mastitis Market is likely to experience growth driven by the adoption of these novel technologies, which aim to improve animal health outcomes and reduce reliance on traditional antibiotics.

    Rising Incidence of Mastitis in Dairy Cattle

    The increasing incidence of mastitis in dairy cattle is a primary driver of the Mastitis Market. Reports indicate that mastitis affects approximately 30 percent of dairy herds, leading to significant economic losses. The condition not only reduces milk production but also increases veterinary costs and impacts milk quality. As dairy farmers seek to mitigate these losses, there is a growing demand for effective treatment and prevention solutions. This trend is likely to propel the Mastitis Market forward, as stakeholders invest in innovative therapies and management practices to address the rising prevalence of this disease.

    Regulatory Pressure for Sustainable Practices

    Regulatory frameworks are increasingly emphasizing sustainable practices in livestock management, which is impacting the Mastitis Market. Governments and organizations are implementing stricter guidelines regarding antibiotic use and animal welfare standards. This regulatory pressure is prompting dairy farmers to seek alternative solutions for mastitis management that align with sustainability goals. As a result, there is a growing market for innovative treatments and preventive measures that comply with these regulations. The Mastitis Market is likely to evolve in response to these changes, as stakeholders adapt to meet both regulatory requirements and consumer expectations for responsible dairy production.

    Market Segment Insights

    By Type: Bovine Mastitis (Largest) vs. Human Mastitis (Fastest-Growing)

    <p>The Mastitis Market shows a distinct segmentation in terms of type, with Bovine Mastitis holding a significant share owing to the large-scale cattle farming and dairy industry demands. This segment is prevalent due to the higher incidence of mastitis in cows, leading to increased treatment expenditures. On the other hand, Human Mastitis, while smaller in proportion, is witnessing rapid growth, driven by rising awareness of breast health issues and the increasing prevalence of mastitis in breastfeeding women.</p>

    <p>Bovine Mastitis (Dominant) vs. Human Mastitis (Emerging)</p>

    <p>Bovine Mastitis remains the dominant force in the Mastitis Market, primarily attributed to extensive dairy farming practices and the consequential need for effective treatment options. The focus on dairy production makes managing bovine mastitis critical for farmers, elevating the demand for veterinary solutions. Conversely, Human Mastitis is emerging rapidly, fueled by heightened awareness of breast health among postpartum women and an increase in healthcare access. This growth is characterized by the introduction of innovative therapies tailored for human patients, alongside educational initiatives aimed at reducing the stigma surrounding this condition, thus positioning it as a significant developing segment in the mastitis landscape.</p>

    By Treatment: Bovine Antibiotics (Largest) vs. Bovine Vaccines (Fastest-Growing)

    <p>In the Mastitis Market, the treatment segment showcases a diverse range of products designed to combat this prevalent dairy cattle disease. Bovine Antibiotics dominate the market due to their established efficacy and widespread use among dairy farmers, capturing a significant market share. In contrast, Bovine Vaccines, while currently smaller, are rapidly gaining traction as awareness of preventive health measures grows, thus representing a compelling shift in industry preferences.</p>

    <p>Bovine Antibiotics (Dominant) vs. Bovine Vaccines (Emerging)</p>

    <p>Bovine Antibiotics remain the cornerstone of mastitis treatment offerings, valued for their effectiveness in managing infections and promoting bovine health. They have a strong presence due to familiarity among veterinarians and farmers, contributing to their dominant status in the market. However, Bovine Vaccines are emerging as a vital alternative, providing a proactive approach to mastitis management. Their rise is fueled by increasing demand for preventive health solutions, with advancements in vaccine technology enhancing their efficacy and appeal. Farmers are progressively inclined to invest in vaccines to minimize antibiotic use, thus promoting a shift toward holistic herd health management.</p>

    By End User: Veterinary Centers (Largest) vs. Hospitals & Clinics (Fastest-Growing)

    <p>In the Mastitis Market, the distribution of market share among end users reveals a dominant presence of veterinary centers, which are the largest segment owing to their specialized focus on animal health care, particularly in the management of mastitis in livestock. Veterinary centers provide dedicated services and expertise, leading to significant consumer preference in the market. Conversely, hospitals and clinics, while smaller in share, are gaining traction as they increasingly incorporate veterinary services and health management solutions that address mastitis treatments.</p>

    <p>End Users: Veterinary Centers (Dominant) vs. Hospitals & Clinics (Emerging)</p>

    <p>Veterinary centers play a crucial role in the Mastitis Market, characterized by their specialized approach to the treatment and prevention of mastitis in dairy cattle and other livestock. This segment is recognized for its focused expertise, offering tailored solutions and veterinary services that ensure enhanced animal health and productivity. In contrast, hospitals and clinics represent an emerging segment, expanding their services to include mastitis treatment. They benefit from integrating advanced medical technology and collaborative healthcare approaches, catering to a growing demand for comprehensive animal health services, thus indicating potential for rapid growth.</p>

    Get more detailed insights about Mastitis Market Research Report - Forecast till 2035

    Regional Insights

    Key Companies in the Mastitis Market market include

    Industry Developments

    • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.
    • Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.
    • Keytruda, developed by Merck & Co., was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.

    Future Outlook

    Mastitis Market Future Outlook

    <p>The Mastitis Market is projected to grow at a 16.73% CAGR from 2024 to 2035, driven by advancements in treatment technologies and increasing awareness among dairy farmers.</p>

    New opportunities lie in:

    • <p>Development of telemedicine platforms for remote diagnosis and treatment monitoring.</p>
    • <p>Investment in AI-driven analytics for early detection of mastitis.</p>
    • <p>Expansion of organic and natural treatment product lines to meet consumer demand.</p>

    <p>By 2035, the Mastitis Market is expected to achieve substantial growth, reflecting evolving industry dynamics.</p>

    Market Segmentation

    Mastitis Market Type Outlook

    • Bovine Mastitis
    • Human Mastitis

    Mastitis Market End User Outlook

    • Veterinary Centers
    • Hospitals & Clinics

    Mastitis Market Treatment Outlook

    • Bovine Antibiotics
    • Bovine Vaccines
    • Human Pain Relievers
    • Human Antibiotics

    Report Scope

    MARKET SIZE 202427.58(USD Billion)
    MARKET SIZE 202532.2(USD Billion)
    MARKET SIZE 2035151.24(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)16.73% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in diagnostic technologies enhance early detection and treatment options in the Mastitis Market.
    Key Market DynamicsRising demand for effective mastitis treatments drives innovation and competition among pharmaceutical and biotechnology companies.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    At what CAGR is the mastitis market projected to grow in the forecast period (2024-2032)?

    Mastitis market projected to grow at approximately 16.73% CAGR during the assessment period (2024-2032).

    How much is the mastitis market worth in the future?

    The valuation of the mastitis market is estimated to increase to USD 53.64 Bn by the end of 2032.

    What are the major tailwinds pushing the growth of the global mastitis market?

    Increasing need for better treatments and government funding support for R&amp;D are major tailwinds pushing the growth of the global mastitis market.

    Which region holds the largest share in the global mastitis market?

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global mastitis market?

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Type (USD Billion)
      2. | | 4.1.1 Bovine Mastitis
      3. | | 4.1.2 Human Mastitis
      4. | 4.2 Healthcare, BY Treatment (USD Billion)
      5. | | 4.2.1 Bovine Antibiotics
      6. | | 4.2.2 Bovine Vaccines
      7. | | 4.2.3 Human Pain Relievers
      8. | | 4.2.4 Human Antibiotics
      9. | 4.3 Healthcare, BY End User (USD Billion)
      10. | | 4.3.1 Veterinary Centers
      11. | | 4.3.2 Hospitals & Clinics
      12. | 4.4 Healthcare, BY Region (USD Billion)
      13. | | 4.4.1 North America
      14. | | | 4.4.1.1 US
      15. | | | 4.4.1.2 Canada
      16. | | 4.4.2 Europe
      17. | | | 4.4.2.1 Germany
      18. | | | 4.4.2.2 UK
      19. | | | 4.4.2.3 France
      20. | | | 4.4.2.4 Russia
      21. | | | 4.4.2.5 Italy
      22. | | | 4.4.2.6 Spain
      23. | | | 4.4.2.7 Rest of Europe
      24. | | 4.4.3 APAC
      25. | | | 4.4.3.1 China
      26. | | | 4.4.3.2 India
      27. | | | 4.4.3.3 Japan
      28. | | | 4.4.3.4 South Korea
      29. | | | 4.4.3.5 Malaysia
      30. | | | 4.4.3.6 Thailand
      31. | | | 4.4.3.7 Indonesia
      32. | | | 4.4.3.8 Rest of APAC
      33. | | 4.4.4 South America
      34. | | | 4.4.4.1 Brazil
      35. | | | 4.4.4.2 Mexico
      36. | | | 4.4.4.3 Argentina
      37. | | | 4.4.4.4 Rest of South America
      38. | | 4.4.5 MEA
      39. | | | 4.4.5.1 GCC Countries
      40. | | | 4.4.5.2 South Africa
      41. | | | 4.4.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 Zoetis (US)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Merck Animal Health (US)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Boehringer Ingelheim (DE)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 Elanco Animal Health (US)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 Cegelec (FR)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 Vetoquinol (FR)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 Huvepharma (BG)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 Phibro Animal Health (US)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | | 5.2.9 Dechra Pharmaceuticals (GB)
      65. | | | 5.2.9.1 Financial Overview
      66. | | | 5.2.9.2 Products Offered
      67. | | | 5.2.9.3 Key Developments
      68. | | | 5.2.9.4 SWOT Analysis
      69. | | | 5.2.9.5 Key Strategies
      70. | 5.3 Appendix
      71. | | 5.3.1 References
      72. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY TYPE
      4. | 6.4 US MARKET ANALYSIS BY TREATMENT
      5. | 6.5 US MARKET ANALYSIS BY END USER
      6. | 6.6 CANADA MARKET ANALYSIS BY TYPE
      7. | 6.7 CANADA MARKET ANALYSIS BY TREATMENT
      8. | 6.8 CANADA MARKET ANALYSIS BY END USER
      9. | 6.9 EUROPE MARKET ANALYSIS
      10. | 6.10 GERMANY MARKET ANALYSIS BY TYPE
      11. | 6.11 GERMANY MARKET ANALYSIS BY TREATMENT
      12. | 6.12 GERMANY MARKET ANALYSIS BY END USER
      13. | 6.13 UK MARKET ANALYSIS BY TYPE
      14. | 6.14 UK MARKET ANALYSIS BY TREATMENT
      15. | 6.15 UK MARKET ANALYSIS BY END USER
      16. | 6.16 FRANCE MARKET ANALYSIS BY TYPE
      17. | 6.17 FRANCE MARKET ANALYSIS BY TREATMENT
      18. | 6.18 FRANCE MARKET ANALYSIS BY END USER
      19. | 6.19 RUSSIA MARKET ANALYSIS BY TYPE
      20. | 6.20 RUSSIA MARKET ANALYSIS BY TREATMENT
      21. | 6.21 RUSSIA MARKET ANALYSIS BY END USER
      22. | 6.22 ITALY MARKET ANALYSIS BY TYPE
      23. | 6.23 ITALY MARKET ANALYSIS BY TREATMENT
      24. | 6.24 ITALY MARKET ANALYSIS BY END USER
      25. | 6.25 SPAIN MARKET ANALYSIS BY TYPE
      26. | 6.26 SPAIN MARKET ANALYSIS BY TREATMENT
      27. | 6.27 SPAIN MARKET ANALYSIS BY END USER
      28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
      29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
      30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER
      31. | 6.31 APAC MARKET ANALYSIS
      32. | 6.32 CHINA MARKET ANALYSIS BY TYPE
      33. | 6.33 CHINA MARKET ANALYSIS BY TREATMENT
      34. | 6.34 CHINA MARKET ANALYSIS BY END USER
      35. | 6.35 INDIA MARKET ANALYSIS BY TYPE
      36. | 6.36 INDIA MARKET ANALYSIS BY TREATMENT
      37. | 6.37 INDIA MARKET ANALYSIS BY END USER
      38. | 6.38 JAPAN MARKET ANALYSIS BY TYPE
      39. | 6.39 JAPAN MARKET ANALYSIS BY TREATMENT
      40. | 6.40 JAPAN MARKET ANALYSIS BY END USER
      41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
      42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
      43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER
      44. | 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
      45. | 6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT
      46. | 6.46 MALAYSIA MARKET ANALYSIS BY END USER
      47. | 6.47 THAILAND MARKET ANALYSIS BY TYPE
      48. | 6.48 THAILAND MARKET ANALYSIS BY TREATMENT
      49. | 6.49 THAILAND MARKET ANALYSIS BY END USER
      50. | 6.50 INDONESIA MARKET ANALYSIS BY TYPE
      51. | 6.51 INDONESIA MARKET ANALYSIS BY TREATMENT
      52. | 6.52 INDONESIA MARKET ANALYSIS BY END USER
      53. | 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
      54. | 6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT
      55. | 6.55 REST OF APAC MARKET ANALYSIS BY END USER
      56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
      57. | 6.57 BRAZIL MARKET ANALYSIS BY TYPE
      58. | 6.58 BRAZIL MARKET ANALYSIS BY TREATMENT
      59. | 6.59 BRAZIL MARKET ANALYSIS BY END USER
      60. | 6.60 MEXICO MARKET ANALYSIS BY TYPE
      61. | 6.61 MEXICO MARKET ANALYSIS BY TREATMENT
      62. | 6.62 MEXICO MARKET ANALYSIS BY END USER
      63. | 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
      64. | 6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT
      65. | 6.65 ARGENTINA MARKET ANALYSIS BY END USER
      66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
      67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
      68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
      69. | 6.69 MEA MARKET ANALYSIS
      70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
      71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
      72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER
      73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
      74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
      75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER
      76. | 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
      77. | 6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT
      78. | 6.78 REST OF MEA MARKET ANALYSIS BY END USER
      79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
      80. | 6.80 RESEARCH PROCESS OF MRFR
      81. | 6.81 DRO ANALYSIS OF HEALTHCARE
      82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
      85. | 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
      86. | 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
      87. | 6.87 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
      88. | 6.88 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
      89. | 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE)
      90. | 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
      91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
      6. | | 7.2.3 BY END USER, 2025-2035 (USD Billion)
      7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      8. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
      9. | | 7.3.2 BY TREATMENT, 2025-2035 (USD Billion)
      10. | | 7.3.3 BY END USER, 2025-2035 (USD Billion)
      11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      12. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
      13. | | 7.4.2 BY TREATMENT, 2025-2035 (USD Billion)
      14. | | 7.4.3 BY END USER, 2025-2035 (USD Billion)
      15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      16. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
      17. | | 7.5.2 BY TREATMENT, 2025-2035 (USD Billion)
      18. | | 7.5.3 BY END USER, 2025-2035 (USD Billion)
      19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      20. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
      21. | | 7.6.2 BY TREATMENT, 2025-2035 (USD Billion)
      22. | | 7.6.3 BY END USER, 2025-2035 (USD Billion)
      23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      24. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
      25. | | 7.7.2 BY TREATMENT, 2025-2035 (USD Billion)
      26. | | 7.7.3 BY END USER, 2025-2035 (USD Billion)
      27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      28. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
      29. | | 7.8.2 BY TREATMENT, 2025-2035 (USD Billion)
      30. | | 7.8.3 BY END USER, 2025-2035 (USD Billion)
      31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      32. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
      33. | | 7.9.2 BY TREATMENT, 2025-2035 (USD Billion)
      34. | | 7.9.3 BY END USER, 2025-2035 (USD Billion)
      35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      36. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
      37. | | 7.10.2 BY TREATMENT, 2025-2035 (USD Billion)
      38. | | 7.10.3 BY END USER, 2025-2035 (USD Billion)
      39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      40. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
      41. | | 7.11.2 BY TREATMENT, 2025-2035 (USD Billion)
      42. | | 7.11.3 BY END USER, 2025-2035 (USD Billion)
      43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      44. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
      45. | | 7.12.2 BY TREATMENT, 2025-2035 (USD Billion)
      46. | | 7.12.3 BY END USER, 2025-2035 (USD Billion)
      47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      48. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
      49. | | 7.13.2 BY TREATMENT, 2025-2035 (USD Billion)
      50. | | 7.13.3 BY END USER, 2025-2035 (USD Billion)
      51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      52. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
      53. | | 7.14.2 BY TREATMENT, 2025-2035 (USD Billion)
      54. | | 7.14.3 BY END USER, 2025-2035 (USD Billion)
      55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      56. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
      57. | | 7.15.2 BY TREATMENT, 2025-2035 (USD Billion)
      58. | | 7.15.3 BY END USER, 2025-2035 (USD Billion)
      59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      60. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
      61. | | 7.16.2 BY TREATMENT, 2025-2035 (USD Billion)
      62. | | 7.16.3 BY END USER, 2025-2035 (USD Billion)
      63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
      65. | | 7.17.2 BY TREATMENT, 2025-2035 (USD Billion)
      66. | | 7.17.3 BY END USER, 2025-2035 (USD Billion)
      67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      68. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
      69. | | 7.18.2 BY TREATMENT, 2025-2035 (USD Billion)
      70. | | 7.18.3 BY END USER, 2025-2035 (USD Billion)
      71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      72. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
      73. | | 7.19.2 BY TREATMENT, 2025-2035 (USD Billion)
      74. | | 7.19.3 BY END USER, 2025-2035 (USD Billion)
      75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      76. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
      77. | | 7.20.2 BY TREATMENT, 2025-2035 (USD Billion)
      78. | | 7.20.3 BY END USER, 2025-2035 (USD Billion)
      79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      80. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
      81. | | 7.21.2 BY TREATMENT, 2025-2035 (USD Billion)
      82. | | 7.21.3 BY END USER, 2025-2035 (USD Billion)
      83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      84. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
      85. | | 7.22.2 BY TREATMENT, 2025-2035 (USD Billion)
      86. | | 7.22.3 BY END USER, 2025-2035 (USD Billion)
      87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      88. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
      89. | | 7.23.2 BY TREATMENT, 2025-2035 (USD Billion)
      90. | | 7.23.3 BY END USER, 2025-2035 (USD Billion)
      91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      92. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
      93. | | 7.24.2 BY TREATMENT, 2025-2035 (USD Billion)
      94. | | 7.24.3 BY END USER, 2025-2035 (USD Billion)
      95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      96. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
      97. | | 7.25.2 BY TREATMENT, 2025-2035 (USD Billion)
      98. | | 7.25.3 BY END USER, 2025-2035 (USD Billion)
      99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      100. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
      101. | | 7.26.2 BY TREATMENT, 2025-2035 (USD Billion)
      102. | | 7.26.3 BY END USER, 2025-2035 (USD Billion)
      103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      104. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
      105. | | 7.27.2 BY TREATMENT, 2025-2035 (USD Billion)
      106. | | 7.27.3 BY END USER, 2025-2035 (USD Billion)
      107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      108. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
      109. | | 7.28.2 BY TREATMENT, 2025-2035 (USD Billion)
      110. | | 7.28.3 BY END USER, 2025-2035 (USD Billion)
      111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      112. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
      113. | | 7.29.2 BY TREATMENT, 2025-2035 (USD Billion)
      114. | | 7.29.3 BY END USER, 2025-2035 (USD Billion)
      115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      116. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
      117. | | 7.30.2 BY TREATMENT, 2025-2035 (USD Billion)
      118. | | 7.30.3 BY END USER, 2025-2035 (USD Billion)
      119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      120. | | 7.31.1
      121. | 7.32 ACQUISITION/PARTNERSHIP
      122. | | 7.32.1

    Mastitis Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓